Dynamics of India's Life Sciences Outsourcing Industry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Dynamics of India's Life Sciences Outsourcing Industry
The tightening of intellectual property rights in India under GATT/TRIPS was a crucial inflection point for pharmaceutical outsourcing in India.


Pharmaceutical Technology


Looking forward

From the author's experience, most pharmaceutical and biotechnology companies came to India for cost savings. All of them stayed for India's quality in scientific talent and infrastructure. And today, most of them are investing in the country for growth and productivity. Some Indian executives have the necessary wherewithal, will, stamina, and long-term commitment to serve the industry and to create value for all involved. As the life sciences industry metamorphoses into its next phase, executives at global biotechnology and pharmaceutical companies need to think of India in a more open-minded, comprehensive, and collaborative manner to fully exploit its potential.

Nailesh A. Bhatt is managing director at Proximare Inc., 100 Overlook Center, Princeton, NJ 08540, tel. 732. 297.7007,

References

1. Global Business Policy Council, "FDI Confidence Index," (A.T. Kearney, Alexandria, VA, 2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here